High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?

Gavin P Reynolds

Abstract
Guidelines for the treatment of schizophrenia limit the use of antipsychotic agents to clinically-established maximum doses. This acknowledges both the absence of additional efficacy of dopamine D2 receptor antagonists above a receptor occupancy threshold, and the increases in side effects that can occur at higher doses. These limits restrict the dosing of combinations of antipsychotics as they do single agents; drugs sharing the major antipsychotic mechanism of D2 receptor antagonism will act additively in blocking these receptors.

Several newer antipsychotic drugs, including aripiprazole and cariprazine, act as partial agonists at the D2 receptor site and avoid action at several other receptors, effects at which are responsible for some non-dopaminergic adverse effects. This pharmacology imparts different characteristics to the drugs resulting often in a more favourable side effect profile. Their partial agonism, along with high affinities for the D2 receptor, also means that these drugs given adjunctively may in part replace, rather than enhance, the D2 antagonism of other antipsychotic agents. This can result in an improvement in certain side effects without loss of antipsychotic efficacy.

This article makes the case for distinguishing the D2 partial agonists from antagonists in defining maximum doses of combined treatments, which would increase the options available to the prescriber, emphasising that pharmacological mechanisms need to be understood in identifying optimal treatments for psychotic illness.

Keywords
Antipsychotic agents, adjunctive treatment, dopamine D2 receptor, antagonists, partial agonists

The dopamine D2 antagonists used as antipsychotic treatments are invaluable for many people with schizophrenia but can be limited by a range of adverse effects. These depend on the pharmacological profile of the antipsychotic drug used, as well as on genetic and other individual features of the patient, and include inter alia extrapyramidal symptoms (EPS), elevated prolactin, sedation, postural hypotension, weight gain and QT interval prolongation. The underlying receptor mechanisms relate to antagonism at, respectively but not exclusively, striatal and pituitary D2 receptors, histamine H1, alpha1 adrenergic, H1 and 5-HT2C receptors and hERG ion channels. In general, these side effects are dose-dependent, consideration of which has prompted the introduction of guidelines aimed at avoiding excessively high doses of antipsychotic drug. Furthermore, it has been established that for most dopamine D2 antagonists a D2 receptor blockade of approximately 60%–70% is adequate for an antipsychotic action and that drug doses above those required to achieve this threshold are likely to increase side effects without a concomitant increase in efficacy (Farde et al., 1992; Kapur et al., 2000).

This argument is also true for combinations of D2 antagonist drugs; the UK consensus guidelines indicate that the ‘high dose’ threshold is reached when the sum of the percentage of the maximum recommended dose for each antipsychotic drug exceeds 100% (Royal College of Psychiatrists, 2014). The rationale is clear: Combining two D2 antagonists at half maximum dose should approximate to the effects of one drug at maximum dose, although it is limited by inconsistencies in determining maximum doses, with newer drugs generally having more constrained dose ranges.

The availability of aripiprazole and cariprazine, as well as brexpiprazole in many countries outside the UK, has provided psychiatry with useful alternatives to the various dopamine D2 receptor antagonists that have been the mainstay in the treatment of psychosis for over 60 years. These three drugs are dopamine D2 receptor partial agonists which also have some further pharmacological properties; for aripiprazole this includes 5-HT1A partial agonism and 5-HT2A antagonism, whilst cariprazine has a partial agonist affinity for D3 higher than that for D2 and antagonist action at 5-HT2B (Frankel and Schwartz, 2017). Both drugs have minimal or, at most, weak effects at histamine H1, muscarinic or adrenergic receptors.

These pharmacological profiles have resulted in the availability of antipsychotic pharmacotherapy that is relatively free of some limiting side effects including hyperprolactinaemia and QT prolongation, as well as reductions in sedation (particularly for cariprazine) and in the requirement for antiparkinsonian medication (particularly for aripiprazole) (Huhn et al., 2019).

There is little evidence to support switching between antipsychotic drugs to improve efficacy (Barnes et al., 2020), although...
recent studies have indicated some differences in which amisulpride, olanzapine and risperidone, as well as clozapine, show small advantages in overall efficacy (Smith et al., 2019). Stronger justification for switching is found in response to side effects which may differ substantially between drugs. Here the D2 partial agonists may demonstrate particular benefits. With these drugs, however, switching from a D2 antagonist may not be immediately necessary; the benefits of aripiprazole (and likely cariprazine too) in reducing drug-induced hyperprolactinaemia, for example, can be seen when the drug is added to current treatment (Zheng et al., 2019). Similarly, adjunctive aripiprazole can ameliorate weight gain and other metabolic problems associated with olanzapine or clozapine treatment (Cooper et al., 2016; Mizuno et al., 2014). Usually there is no deterioration of psychotic symptoms associated with adding a dopamine partial agonist; further symptomatic improvement may even be seen (e.g. Zheng et al., 2019). Such adjunctive prescribing would be off-label but has a strong evidence base. It could, however, also serve as an initial step towards D2 partial agonist monotherapy, prior to a gradual withdrawal of the D2 antagonist drug.

Combination of two antipsychotic agents in this way may exceed the high dose threshold. Such cumulative doses are perceived as high risk and understandably may require explicit justification for their prescription. British Association for Psychopharmacology guidelines indicate that antipsychotic augmentation to address inadequate symptom response should only be considered after other treatment options have been exhausted, including ‘several, adequate, sequential trials of antipsychotic monotherapy’ (Barnes et al., 2020). This both reflects and guides current UK practice where switching is generally preferred to augmentation with another antipsychotic drug, despite the acknowledged paucity of supportive evidence. This often means that drug combinations are avoided with alternative, but perhaps sub-optimal, strategies being employed.

As mentioned above, the pharmacological basis for this high dose risk is clear; additional blockade of D2 receptors above what is necessary for an antipsychotic response will increase the liability for dopaminergic side effects such as EPS and prolactin secretion without increasing efficacy. Furthermore, and depending on the particular drugs being combined, other receptor-mediated side effects are likely to increase, some of which, such as metabolic effects and QT prolongation, may contribute to increased mortality. However, this pharmacological argument does not consistently hold up for the combination of partial agonists with antagonists. In terms of the main antipsychotic mechanism, drug action at the dopamine D2 receptor, the dopamine D2 partial agonists should be differentiated from D2 antagonists. As can be seen in their effects in avoiding, and reversing, D2 antagonist-induced hyperprolactinaemia, adjunctive partial agonists can ameliorate, rather than enhance, unwanted dopaminergic effects of D2 antagonists. Aripiprazole and cariprazine have high (sub-nanomolar) affinities at the D2 receptor greater than most D2 antagonists (Frankel and Schwartz, 2017). Thus they will preferentially bind to the receptor site, resulting in replacing antagonism with partial agonism, thereby providing a level of receptor stimulation which depends on the drug’s intrinsic activity; for aripiprazole this is around 25% of that of dopamine (Così et al., 2006).

This provides a strong argument for differentiating the D2 partial agonists from the D2 antagonist drugs and considering them a separate class when it comes to combining drugs for the optimal treatment of people with psychotic illness. Of course, polypharmacy is to be avoided where possible and drugs need to be given at the lowest dose consistent with optimising efficacy and minimising side effects. However, it is clearly wrong to restrict adjunctive use of D2 partial agonists, where they may have clinical value, on the basis of the inappropriate application of a ‘maximum cumulative dose’ concept.

As a postscript, I suggest that the issue highlighted here is related to the common view of ‘antipsychotic agents’ as a single drug class or, at best, one divided into first- and second-generation antipsychotics. The application of neuroscience-based nomenclature, in which drugs are differentiated on the basis of their pharmacological mechanisms (Nutt and Blier, 2016), takes one step towards avoiding this oversimplification and its consequences for psychiatric pharmacotherapy.

Acknowledgements

I am grateful to Dr Olga McGowan for valuable discussion.

Declaration of conflicting interests

The author declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: I have received honoraria for lectures and/or advisory board attendance from the following pharmaceutical companies: Kang Hong, Lundbeck, Otsuka and Sumitomo.

Funding

The author received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Gavin P Reynolds https://orcid.org/0000-0001-9026-7726

References

Barnes TR, Drake R, Paton C, et al. (2020) Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol 34: 3–78.

Cooper SJ, Reynolds GP, Barnes T, et al. (2016) BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol 30: 717–748.

Così C, Carilla-Durand E, Assié MB, et al. (2006) Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur J Pharmacol 555: 135–144.

Frankel JS and Schwartz TL (2017) Brexpiprazole and cariprazine: Distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol 7: 29–41.

Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. Lancet 394: 939–951.

Kapur S, Zipursky R, Jones C, et al. (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: A
double-blind PET study of first-episode schizophrenia. *Am J Psychiatry* 157: 514–520.

Mizuno Y, Suzuki T, Nakagawa A, et al. (2014) Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: A systematic review and meta-analysis. *Schizophr Bull* 40: 1385–1403.

Nutt DJ and Blier P (2016) Neuroscience-based nomenclature (NbN) for journal of psychopharmacology. *J Psychopharmacol* 30: 413–415.

Royal College of Psychiatrists (2014) Consensus statement on high-dose antipsychotic medication. Royal College of Psychiatrists. College Report CR190, 2014.

Smith RC, Leucht S and Davis JM (2019) Maximizing response to first-line antipsychotics in schizophrenia: A review focused on finding from meta-analysis. *Psychopharmacology* 236: 545–559.

Zheng W, Cai DB, Yang XH, et al (2019) Adjunctive aripiprazole for antipsychotic-related hyperprolactinaemia in patients with first-episode schizophrenia: A meta-analysis. *Gen Psychiat* 32: e100091.
Commentary on ‘High dose antipsychotic polypharmacy and dopamine partial agonists – time to rethink guidelines?’ by Prof Gavin Reynolds

Carol Paton. Joint-head. Prescribing Observatory for Mental Health. Honorary Research Fellow. Division of Psychiatry, Imperial College London, Du Cane Road, London W12 0NN, United Kingdom. Carol.Paton@nhs.net

Thomas R. E. Barnes. Professor emeritus of clinical psychiatry. Division of Psychiatry, Imperial College London, London, United Kingdom

Clinical guidelines for the treatment of schizophrenia consistently recommend the use of a single antipsychotic in a standard dose (Barnes et al., 2020; National Institute for Health and Care Excellence, 2014; Galletly et al., 2016); this strategy is underpinned by both a large body of evidence supporting the efficacy of individual antipsychotic medications and by tolerability data that have been systematically, although not always comprehensively, garnered (Pope et al., 2010). These guidelines further recommend switching to an alternative antipsychotic medication if the first antipsychotic is not tolerated or the illness fails to respond, although the paucity of supportive evidence for such switching is acknowledged. Should there be a persistent lack of adequate therapeutic response, timely progression to clozapine treatment should be the next step, in advance of the use of high-dosage antipsychotic medication or combined antipsychotic medication strategies (which commonly result in a high-dose regimen), for which the evidence regarding treatment outcomes and safety is considerably slimmer.

Reynolds argues that, when added to another antipsychotic medication, D₂ partial agonists reduce metabolic and prolactin-related side effects and potentially improve symptom control: therefore the use of such combinations should be considered earlier when seeking to optimise treatment for schizophrenia. But any additional beneficial effect on symptoms and side-effects with a D₂ partial agonist/D₂ antagonist combination is likely to be modest and the combination may be associated with new side effects, so a favourable balance of risks and benefits cannot be assumed. Most of the clinical literature relating to D₂ partial agonists focuses on aripiprazole as this antipsychotic medication was first in class. Therefore, aripiprazole is used to expand on these points below.

Efficacy and tolerability of aripiprazole as monotherapy

While aripiprazole has evident antipsychotic efficacy, it may be slightly less effective overall for treating the symptoms of schizophrenia than the more commonly used D₂ antagonists (Leucht et al., 2013; Tiihonen et al., 2019), suggesting that D₂ partial agonism may provide less than optimal control of symptoms in some cases. There are a further group of patients whose illness has shown an insufficient response to non-clozapine antipsychotic medication that is not related to factors such as poor adherence or comorbid substance use. Such treatment-resistant schizophrenia may have a distinct pathophysiology involving a range of neurobiological pathways (Potkin et al., 2020). Therefore, pharmacological strategies that are limited to modulating D₂ receptor activity, either as monotherapy or in combination, may have minimal if any effect on symptoms and pursuing such strategies could result in an avoidable delay in initiating clozapine treatment, potentially worsening outcomes (Shah et al., 2018; Yoshimura et al., 2017).

When used alone, aripiprazole is undoubtedly relatively well tolerated with respect to metabolic and prolactin-related side effects (Leucht et al., 2013) but it is not free of side effects, with treatment-emergent akathisia, insomnia, headache and nausea reported for more than 1 patient in 10 in clinical trials (Aripiprazole SmPC). With respect to QTc prolongation, epidemiological studies have linked aripiprazole to weak/moderate tosardogenicity (Polcwartek et al., 2015). Further, recent evidence points to an association between D₂ partial agonists and the development of impulse control disorders (Corbeil et al., 2021; Grall-Bronnec et al., 2016). Therefore, as is the case for all antipsychotic medications, the decision to prescribe aripiprazole should take into consideration the potential harms associated with this medication and ongoing clinical review is essential.

Efficacy and tolerability of aripiprazole in combination with another antipsychotic medication

While to our knowledge there are no randomised controlled trials of aripiprazole augmentation of non-clozapine antipsychotic medication, the real life effectiveness of such combinations has been reported by Tiihonen et al. (2019). In a Swedish, population-based cohort of 62,500 patients with an established diagnosis of schizophrenia, those patients who were prescribed clozapine, olanzapine or a long-acting injectable antipsychotic preparation as monotherapy were less likely to be readmitted to hospital than those prescribed aripiprazole combined with a non-clozapine antipsychotic. Further, olanzapine monotherapy fared slightly better than olanzapine combined with aripiprazole. Thus, these findings failed to suggest any systematic efficacy advantage for the addition of aripiprazole to a non-clozapine antipsychotic medication.

With respect to aripiprazole augmentation of clozapine, a meta-analysis of mostly very small randomised controlled trials found no advantage with respect to psychotic symptoms in clozapine responders who received aripiprazole as a strategy to manage weight gain but a potential modest advantage with respect to improvement in negative symptoms where the illness had not responded to clozapine (Srisurapanon et al., 2015). In the naturalistic study by Tiihonen et al. (2019) described above, the combination of clozapine and aripiprazole was most effective
in preventing readmission but, compared with clozapine mono-
therapy, the effect size was small. When considered together,
these studies do not exclude a modest advantage for an individ-
ual treatment trial of the combination over clozapine monother-
apy for some particular patients, but the evidence so far falls short of
supporting routine use.
Aripiprazole binds strongly to D2 receptors but the degree of
dopamine blockade it produces is limited as it is a partial agonist
rather than an antagonist. Through this mechanism, adjunctive
aripiprazole has been shown to reverse the hyperprolactinaemia
that is associated with some potent D2 antagonists, such as ris-
eridone (Yasui-Furukori et al., 2010). However hyperprolactinae-
ma that is asymptomatic does not always require treatment and
where it is symptomatic or the patient is otherwise at greater risk
of sequelae, the most logical strategy would be to switch to an
antipsychotic medication with a low propensity for elevating
plasma prolactin.
With respect to the amelioration of weight gain associated
with antipsychotic treatment, published meta-analyses (Choi,
2015; Srisurapanont et al., 2015) have concluded that the addi-
tion of aripiprazole to clozapine or olanzapine results in a mean
weight change of around -2 kg compared with clozapine or olan-
zapine monotherapy. This mean change is modest and while it
does not exclude a larger effect in some patients, it suggests that
for the majority the effect on body weight is unlikely to be clini-
cally relevant. The use of adjunctive aripiprazole to reduce
weight gain in patients receiving antipsychotic medications other
than clozapine or olanzapine has not been systematically tested.
While the BAP guidelines for the management of weight gain,
metabolic disturbances and cardiovascular risk associated with
psychosis and antipsychotic treatment (Cooper et al, 2016) iden-
tified augmentation of clozapine or olanzapine with aripiprazole
as a possible intervention for weight gain, it added the caveat that
the possible disadvantages of such polypharmacy should be con-
considered versus the degree of benefit obtained. For example, the
meta-analysis by Choi (2015) also noted that there were clear
signals for treatment-emergent akathisia and nausea, along with
one report of sinus tachycardia and two of significant worsening
of psychotic symptoms in the aripiprazole augmentation arms.
The meta-analysis by Srisurapanont (2015) reported modest
improvement in LDL cholesterol with aripiprazole augmentation
but did not find any beneficial effects of the combination with
respect to fasting plasma glucose, although it should be noted
that the durations of the included studies were short, ranging
from 8 to 24 weeks.

**Definition of high-dose antipsychotic medication and recommendations in evidence-based clinical guidelines**

A number of approaches have been used to determine whether a combination of antipsychotic medication is considered to be high dose or not (Barnes et al., 2014); the most common are (1) the use of ‘chlorpromazine equivalents’ where the doses of each antipsychotic medication are converted to an equivalent dose of chlorpromazine, based partially on known affinity for D2 receptors, and a total equivalent dose of chlorpromazine above 1000 mg is defined as a high dose, and; (2) the more commonly used ‘percentage method’ where the percentages of the maximum licensed dose for each antipsychotic medication co-prescribed are added and a cumulative dose of more than 100% is defined as a high dose. While both methods are essentially arbitrary and have their limitations, they provide a dosage threshold above which the evidence suggests that the risk-benefit balance becomes more uncer-
tain and potentially unfavourable (Leucht et al., 2020) and which
should be a prompt that such regimens should be prescribed as
individual therapeutic trials, with close monitoring of target
symptoms and potential side effects. Guideline recommendations
relating to the use of high-dose or combined antipsychotic medi-
cation strategies are not based simply on whether a dosage
threshold has been exceeded, but consider the available evidence
relating to efficacy and safety, to inform the rational prescription
of such regimens. Nevertheless, as the evidence base is con-
stantly developing and changing, there is a need to keep all
guideline recommendations under review.

**Conclusion**

Where evidence-based medication strategies (including clozap-
ine) for schizophrenia have failed or are not tolerated, an indi-
nual therapeutic trial of combined antipsychotic medications is
a potential treatment option. In this context, a trial of aripiprazole
augmentation of another antipsychotic medication may offer
worthwhile benefits for some patients in some clinical circum-
stances. However, given the relatively poor evidence base under-
pinning the use of combined antipsychotic medications, the
advice that other pharmacological interventions with more con-
sistent evidence for a favourable risk-benefit balance should be
given priority and that if such a regimen is prescribed there is a
responsibility to document the rationale for the chosen combina-
tion and carefully monitor the benefits and harms, should support
judicious prescribing.

**References**

Barnes TRE, Drake R, Paton C, et al. (2020) Evidence-based guidelines
for the pharmacological treatment of schizophrenia: Updated recom-
mendations from the British Association for Psychopharmacology. J
Psychopharmacol 34: 3–78.
Barnes TRE, Dye S, Ferrier N, et al. (2014) Consensus statement on high-
dose antipsychotic medication. Royal College of Psychiatrists. Col-
lege Report CR190.
Choi YJ (2015) Efficacy of adjunctive treatments added to olanzapine or
clozapine for weight control in patients with schizophrenia: A sys-
temic review and meta-analysis. Sci World J 2015: 970730.
Cooper SJ, Reynolds GP, Barnes TRE, et al. (2016) BAP guidelines on
the management of weight gain, metabolic disturbances and cardio-
vascular risk associated with psychosis and antipsychotic drug treat-
ment. J Psychopharmacol 30: 717–748.
Corbeil O, Corbeil S, Dorval M, et al. (2021) Problem gambling associ-
ated with aripiprazole: A nested case-control study in a first-episode
psychosis program. CNS Drugs 35: 461–468.
Galletly C, Castle D, Dark F, et al. (2016) Royal Australian and New
Zealand College of Psychiatrists clinical practice guidelines for the
management of schizophrenia and related disorders. Aust N Z J Psy-
chiatry 50: 410–472.
Grall-Bronnec M, Sauvaget A, Perrouin F, et al. (2016) Pathological
gambling associated with aripiprazole or dopamine replacement
therapy. Do patients share the same features? A review. J Clin Psy-
chopharmacol 36: 63–70.
Leucht S, Cipriani A, Spinelli L, et al. (2013) Comparative efficacy and
tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-
treatments meta analysis. Lancet 382: 951–962.
Leucht S, Crippa A, Siafis S, et al. (2020) Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. *Am J Psychiatry* 177: 342–353.

National Institute for Health and Care Excellence (2014) Psychosis and schizophrenia in adults: Prevention and management. Clinical Guideline 178. 2014. Available at: https://www.nice.org.uk/guidance/cg178

Polciwiartek C, Sneider B, Graff C, et al. (2015) The cardiac safety of aripiprazole in patients at high risk for torsade: A systematic review with a meta-analytic approach. *Psychopharmacology* 232: 3297–3308.

Pope A, Adams C, Paton C, et al. (2010) Assessment of adverse effects in clinical studies of antipsychotic medication: Survey of methods used. *Br J Psychiatry* 197: 67–72.

Potkin SG, Kane JM, Correll CU, et al. (2020) The neurobiology of treatment-resistant schizophrenia: Paths to antipsychotic resistance and a roadmap for future research. *NPJ Schizophrenia* 6: 1.

Shah P, Iwata Y, Plitman E, et al. (2018) The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review. *Psychiatry Res* 268: 114–122.

Srisurapanont M, Suttajit S, Maneton N, et al. (2015) Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: A systematic review and meta-analysis or randomized-controlled trials. *J Psychiatr Res* 62: 38–47.

Summary of Product Characteristics. Aripiprazole. Electronic Medicines Compendium. Available at: https://www.medicines.org.uk/emc/product/7969/smpc#UNDESIRABLE_EFFECTS

Tiihonen J, Taipale H, Mehtala J, et al. (2019) Association of antipsychotic polipharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. *JAMA Psychiatry* 76: 499–507.

Ucok A, Ugur C, Karabulut S, et al. (2015) Delayed initiation of clozapine may be related to poor response to treatment-resistant schizophrenia. *Int Clin Psychopharmacol* 30: 290–295.

Yasui-Furukori N, Furukori H, Sugawara N, et al. (2010) Dose dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. *J Clin Psychopharmacol* 30: 596–599.

Yoshimura B, Yada Y, So R, et al. (2017) The critical treatment window of clozapine in treatment-resistant schizophrenia: Secondary analysis of an observational study. *Psychiatry Res* 250: 65–70.
Response to Paton and Barnes

Arguably the biggest concern in schizophrenia research is that of people with schizophrenia whose symptoms do not respond to standard antipsychotic agents (James Lind Alliance, 2011). Until more effective drugs are introduced which address this problem, it is important to provide a therapeutic environment that offers clinicians and their patients the most flexibility in treatment choice without restrictions that are not firmly grounded in evidence. To my mind, this includes the opportunity to provide a relatively safe treatment with a D2 partial agonist additional to a D2 antagonist, while recognising of course that, as with all pharmacotherapy, there is a balance to be struck between risk and benefit.

Paton and Barnes have prepared an extensive response to my commentary, starting by summarising the guidelines for the treatment of schizophrenia. These recommend monotherapy and switching to an alternative antipsychotic agent if this is not tolerated or if the illness fails to respond. Only the first of these reasons to switch has a strong evidence base. They also discuss at length the evidence for the efficacy and tolerability, or otherwise, of aripiprazole treatment for schizophrenia. They repeatedly describe benefits of adjunctive aripiprazole as modest; however, less than modest supporting evidence is no barrier to inclusion in guidelines, as we see with the recommendation to switch drugs for lack of response. We can recognise this as a pragmatic recommendation – ‘what else can be done?’ - in the hope that some individual factor may result in improvement, but evidence suggests it remains unlikely to be effective.

There is much opportunity for further debate around the effects of aripiprazole that Paton and Barnes discuss so comprehensively. One point they make is, however, misleading. They reiterate a comment in the abstract of Polcwiartek et al. (2015) that epidemiological studies have linked aripiprazole to weak/moderate torsadogenicity. Yet the authors also state that a ‘lack of adequate data . . . confounds the interpretation of any epidemiological findings’. More importantly, the main finding of this review and meta-analysis of aripiprazole’s cardiac safety in patients at high risk for torsade is that QTc prolongation risk is lower compared with both placebo and active controls. In a more recent population-based Danish study (Polcwiartek et al., 2020), the same research group report that, while antipsychotic prescribing in people with schizophrenia was associated with a greater frequency of abnormal ECGs compared to non-psychiatric control subjects, this was not true for aripiprazole which was additionally associated with a decreased risk of QTc prolongation. It would be reasonable to conclude that aripiprazole is relatively safe in terms of this measure of cardiac toxicity.

One final point: while I have not specifically considered the adjunctive use of partial D2 agonists with clozapine, Paton and Barnes have helpfully drawn attention to the study of Tiihonen et al. (2019). The key finding from this nationwide Finnish study is that aripiprazole and clozapine polypharmacy is significantly more effective in reducing rehospitalization than clozapine or any antipsychotic monotherapy alone. While the effect size may be small, we are reminded by the authors that this may be an underestimate as adjunctive treatment is generally in response to a worsening of symptoms with monotherapy. Tiihonen et al. (2019) conclude that a rational polypharmacy with two particular drugs of differing receptor profiles appears feasible, and that treatment guidelines which discourage all antipsychotic polypharmacy should be modified accordingly. While this has not been the main point of my commentary, such evidence-based polypharmacy would be facilitated by the removal of a ‘high dose’ restriction on adjunctive D2 partial agonists that has no pharmacological rationale.

References

James Lind Alliance (2011) Schizophrenia priority setting partnership. Available at: www.jla.nihr.ac.uk/priority-setting-partnerships/schizophrenia/top-10-priorities/ (accessed 26 April 2021).

Polcwiartek C, Sneider B, Graff C, et al. (2015) The cardiac safety of aripiprazole in patients at high risk for torsade: A systematic review with a meta-analytic approach. Psychopharmacology 232: 3297–3308.

Polcwiartek C, Kragholm K, Hansen SM, et al. (2020) Electrocardiogram characteristics and their association with psychotropic drugs among patients with schizophrenia. Schizophr Bull 46: 354–362.

Tiihonen J, Taipale H, Mehtala J, et al. (2019) Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry 76: 499–507.